ITCI Stock Overview
A biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Intra-Cellular Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$131.65 |
| 52 Week High | US$131.67 |
| 52 Week Low | US$64.09 |
| Beta | 0.70 |
| 1 Month Change | 2.37% |
| 3 Month Change | 56.73% |
| 1 Year Change | 90.74% |
| 3 Year Change | 116.60% |
| 5 Year Change | 732.17% |
| Change since IPO | 1,216.50% |
Recent News & Updates
Recent updates
Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition
Mar 05What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies
Jan 13Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
Dec 30
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
Dec 09Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%
Nov 07Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Sep 22Peaking Back In On Intra-Cellular Therapies
Sep 04Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For
Jul 27Intra-Cellular Brightens MDD Outlook With Caplyta Success
Jun 19Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Shareholder Returns
| ITCI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.3% | 1.7% | 0.6% |
| 1Y | 90.7% | 1.1% | 7.9% |
Return vs Industry: ITCI exceeded the US Pharmaceuticals industry which returned 1.1% over the past year.
Return vs Market: ITCI exceeded the US Market which returned 7.9% over the past year.
Price Volatility
| ITCI volatility | |
|---|---|
| ITCI Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ITCI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ITCI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 860 | Sharon Mates | www.intracellulartherapies.com |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing lumateperone, which is in Phase 3 clinical trial for the treatment of major depressive disorder, as well as schizophrenia in pediatric patients, bipolar disorder, and irritability associated with autism spectrum disorder.
Intra-Cellular Therapies, Inc. Fundamentals Summary
| ITCI fundamental statistics | |
|---|---|
| Market cap | US$14.00b |
| Earnings (TTM) | -US$74.68m |
| Revenue (TTM) | US$680.85m |
20.6x
P/S Ratio-187.5x
P/E RatioIs ITCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITCI income statement (TTM) | |
|---|---|
| Revenue | US$680.85m |
| Cost of Revenue | US$293.08m |
| Gross Profit | US$387.77m |
| Other Expenses | US$462.44m |
| Earnings | -US$74.68m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | 56.95% |
| Net Profit Margin | -10.97% |
| Debt/Equity Ratio | 0% |
How did ITCI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 16:38 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intra-Cellular Therapies, Inc. is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| Robert Hazlett | BTIG |